论文部分内容阅读
目的观察吉非替尼一线治疗合并胸腔积液晚期非小细胞肺癌(NSCLC)疗效。方法 25例符合条件患者分对照组12例,治疗组13例口服吉非替尼,两组治疗后每3个月进行疗效评估及生存期观察。结果治疗组客观缓解率7.7%,疾病控制率69.2%,中位生存期10个月;对照组分别为0%、8.3%及5个月,治疗组后两指标明显优于对照组。结论吉非替尼对合并恶性胸腔积液晚期NSCLC有一定疗效,能提高其生存期。
Objective To observe the efficacy of first-line gefitinib in the treatment of advanced non-small cell lung cancer (NSCLC) with pleural effusion. Methods Twenty-five eligible patients were divided into control group (n = 12) and treatment group (n = 13) were given gefitinib. Efficacy evaluation and survival of the two groups were performed every 3 months after treatment. Results In the treatment group, the objective response rate was 7.7%, the disease control rate was 69.2%, and the median survival time was 10 months. The control group was 0%, 8.3% and 5 months respectively. The two indexes in the treatment group were significantly better than those in the control group. Conclusion Gefitinib has some curative effect on advanced NSCLC with malignant pleural effusion, and can improve its survival.